Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 2/20 | 0.52 |
| ▸ | CD74 | P04233 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 6/20 | 0.51 |
| ▸ | TNIK | Q9UKE5 | 8/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2149337 | 0.84 | TNIK (0.49) | MIFCD74IDO1TNIKPOLB | |
| SCHEMBL3047009 | 0.83 | CD74 (0.49) | MIFCD74IDO1TNIKPOLB | |
| SCHEMBL10991734 | 0.81 | IDO1 (0.54) | MIFIDO1POLBKMT2ANPC1 | |
| SCHEMBL8877584 | 0.81 | MET (0.49) | MIFCD74IDO1TNIKPOLB | |
| SCHEMBL4413144 | 0.78 | HPGD (0.64) | MIFCD74IDO1TNIKPOLB | |
| SCHEMBL9716002 | 0.77 | MIF (0.44) | MIFCD74IDO1TNIKPOLB | |
| SCHEMBL10915913 | 0.75 | MAPK1 (0.72) | MIFIDO1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL5539784 | 0.74 | CD74 (0.42) | MIFCD74IDO1TNIKPOLB | |
| SCHEMBL5539787 | 0.74 | MEN1 (0.59) | POLBKMT2AALDH1A1 | |
| SCHEMBL13962146 | 0.73 | GPR55 (0.42) | MIFCD74IDO1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | UCB PHARMA, S.A. (BE) | 2010-09-02 | — | — | US | claimed |
| EP-2152262-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB Pharma, S.A. (BE) | 2010-02-17 | — | — | EP | claimed |
| WO-2008132142-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB PHARMA S.A. (BE) | 2008-11-06 | — | — | WO | claimed |
| WO-2008132139-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB PHARMA S.A. (BE) | 2008-11-06 | — | — | WO | claimed |
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | UCB PHARMA, S.A. (BE) | 2010-09-02 | — | — | US | disclosed |
| EP-2152262-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB Pharma, S.A. (BE) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008132142-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB PHARMA S.A. (BE) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008132139-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB PHARMA S.A. (BE) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | CNR2, CNR1, SLC18A2 | MIF 4473/4885CD74 4847/4885IDO1 1577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.